OrbusNeich Begins China Clinical Trial of Bio-Engineered Stent

OrbusNeich has enrolled the first patient in a China clinical trial of its Genous Bio-engineered R stent. The stent, which has been available in Europe since 2005, is coated with an antibody that captures a patient’s endothelial progenitor cells from the bloodstream. The company says the cells promote rapid healing of the blood vessel’s lining, helping to protect against thrombus and to minimize restenosis. More details...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.